Trasylol Clinical Benefit To Be Reviewed By FDA Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Cardiovascular & Renal Drugs Advisory Committee will also consider reports of hypersensitivity and renal and cardiovascular risk linked to Bayer’s aprotinin injection at its Sept. 21 meeting.
You may also be interested in...
Trasylol Not Associated With Renal/Heart Failure, MI, Stroke, Cmte. Says
FDA’s Cardiovascular & Renal Drugs Advisory Committee reiterate risk of renal dysfunction associated with aprotinin at its Sept. 21 meeting.
Trasylol Not Associated With Renal/Heart Failure, MI, Stroke, Cmte. Says
FDA’s Cardiovascular & Renal Drugs Advisory Committee reiterate risk of renal dysfunction associated with aprotinin at its Sept. 21 meeting.
Trasylol Public Health Advisory Cites Kidney, Heart Attack, Stroke Risks
FDA will convene an advisory committee meeting to discuss the risks and benefits of Bayer's transfusion-sparing agent following risk reports.